Barclays analyst Matt Miksic raised the firm’s price target on InMode to $45 from $44 and keeps an Overweight rating on the shares. The analyst says Q4 strength in sales momentum and gross margins raised confidence in the durability of the company’s business, helping to ease concerns over the potential risks to end-market demand for aesthetics capital equipment and procedures.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INMD:
- InMode Up as Q4 Results Beat Estimates
- InMode Reports Fourth Quarter and Full Year 2022 Financial Results; Record Quarterly Revenue of $133.6M Represents 21% Year-Over-Year Growth
- InMode sees FY23 adjusted EPS $2.58-$2.60, consensus $2.64
- InMode reports Q4 adjusted EPS 78c, consensus 67c
- InMode put volume heavy and directionally bearish
